Of note, there were no patients with cSCC included in the DESTINY‐PanTumor02 trial, which demonstrated the efficacy of trastuzumab deruxtecan in HER2 overexpressing solid tumors [13]. The gene discussed is ERBB2; the disease is skin squamous cell carcinoma.